Skip to main content

Table 1 Patients’ Demographic and Clinical Characteristics, Tumor Features, and Outcome

From: Mitochondrial apurinic/apyrimidinic endonuclease 1 enhances mtDNA repair contributing to cell proliferation and mitochondrial integrity in early stages of hepatocellular carcinoma

Gender (M:F) 15:5
Age (years) 73 [62–77]
HBV positivity (%) 1 (5%)
HCV positivity (%) 6 (30%)
NASH (%) 3 (15%)
Alcohol abuse (%) 7 (35%)
MELD score 7 [6–10]
AFP, (ng/mL) 7.5 [3.2–23.5]
CEA, (ng/mL) 1.7 [1.1–3.3]
CA 19.9 (UI/mL) 16.9 [9.9–19.3]
Tumor number (%)  
- 1 14 (70%)
- 2 4 (20%)
- 3 2 (10%)
Satellites lesions (%) 3 (15%)
Tumor max diameter (cm) 4.3 [3–10.8]
Edmonson-Steiner grading (%)
 - G1 4 (20%)
 - G2 12 (60%)
 - G3 4 (20%)
Microvascular invasion (%) 7 (35%)
Tumor staging (%)
 - T1 7 (35%)
 - T2 7 (35%)
 - T3 3 (15%)
 - T4 3 (15%)
Tumor recurrence (%) 10 (50%)
Recurrence time, (months) 25.4 [7.4–33.5]
  1. Continuous variables are expressed by median [interquartile range], Categorical variables by percentage
  2. AFP alphafetoprotein; CA 19.9 Carbohydrate Antigen 19.9, CEA carcinoembryonic antigen, HBV hepatitis B virus, HCV hepatitis C virus, NASH non alcoholic steatohepatitis, MELD Model for end-stage liver disease